Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy targets dyslipidemia by utilizing two distinct mechanisms. Plant sterol esters, which are structurally similar to cholesterol, competitively inhibit the absorption of dietary and biliary cholesterol in the small intestine by interacting with the Niemann-Pick C1-like 1 (NPC1L1) transporter, thereby reducing low-density lipoprotein (LDL) cholesterol levels. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain omega-3 fatty acids that primarily reduce serum triglyceride levels. They act as agonists for peroxisome proliferator-activated receptor alpha (PPAR-alpha) and inhibit diacylglycerol O-acyltransferase (DGAT), leading to decreased hepatic very-low-density lipoprotein (VLDL) synthesis and increased fatty acid oxidation. This combination is widely used in dietary supplements and functional foods to provide a synergistic approach to cardiovascular health by addressing both cholesterol and triglyceride levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plant sterol esters + eicosapentaenoic acid + docosahexaenoic acid.